Pioglitazone News and Research

RSS
FDA approves ONGLYZA to treat type 2 diabetes patients with renal impairment

FDA approves ONGLYZA to treat type 2 diabetes patients with renal impairment

Avandia label revised as per FDA directive

Avandia label revised as per FDA directive

FDA accepts Merck's JANUMET extended-release formulation NDA for type 2 diabetes

FDA accepts Merck's JANUMET extended-release formulation NDA for type 2 diabetes

Takeda, Zinfandel enter global licensing agreement for TOMM40 biomarker assay for Alzheimer's disease

Takeda, Zinfandel enter global licensing agreement for TOMM40 biomarker assay for Alzheimer's disease

Takeda completes settlements in patent litigation over generic ACTOS, ACTOplus met, and duetact ANDAs

Takeda completes settlements in patent litigation over generic ACTOS, ACTOplus met, and duetact ANDAs

Scientists discover key molecular events in immune system that contribute to inflammatory bowel disease

Scientists discover key molecular events in immune system that contribute to inflammatory bowel disease

Some key molecular events in immune system contribute to inflammatory bowel disease: Scientists

Some key molecular events in immune system contribute to inflammatory bowel disease: Scientists

VYTORIN reduces major vascular events in patients with chronic kidney disease

VYTORIN reduces major vascular events in patients with chronic kidney disease

Type 2 diabetes market in Mexico to grow to $1.22 billion in 2014: Report

Type 2 diabetes market in Mexico to grow to $1.22 billion in 2014: Report

Diabetic drug may retard growth of fluid-filled cysts in PKD: Research

Diabetic drug may retard growth of fluid-filled cysts in PKD: Research

ACG 75th Scientific Meeting to review advances in gastrointestinal research, treatment of digestive diseases

ACG 75th Scientific Meeting to review advances in gastrointestinal research, treatment of digestive diseases

Study investigates effectiveness of potential treatment for Non-alcoholic steatohepatitis

Study investigates effectiveness of potential treatment for Non-alcoholic steatohepatitis

Takeda underscores commitment to ACTOS following FDA and EMA announcements for rosiglitazone

Takeda underscores commitment to ACTOS following FDA and EMA announcements for rosiglitazone

Avandia restricted by the FDA and EMEA

Avandia restricted by the FDA and EMEA

FDA reviews Actos drug for bladder cancer risk

FDA reviews Actos drug for bladder cancer risk

Two diabetes medications increase risk of heart attack, failure: Study

Two diabetes medications increase risk of heart attack, failure: Study

Intellect Neurosciences receives patent for insulin sensitizer drugs

Intellect Neurosciences receives patent for insulin sensitizer drugs

Alkermes reports $42.3 million revenue for first-quarter fiscal 2011

Alkermes reports $42.3 million revenue for first-quarter fiscal 2011

Postmenopausal women with diabetes taking TZDs at increased fracture risk

Postmenopausal women with diabetes taking TZDs at increased fracture risk

New understanding on insulin resistance, action of diabetes drugs may lead to safer medication

New understanding on insulin resistance, action of diabetes drugs may lead to safer medication